<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0408210903
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Olneda
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLMESARTAN MEDOXOMIL,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        77
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Olneda&trade; contains two substances called olmesartan medoxomil and<br />amlodipine (as amlodipine besilate). Both of these substances help to<br />control high blood pressure.<br />&bull; Olmesartan medoxomil belongs to a group of medicines called<br />&ldquo;angiotensin-II receptor antagonists&rdquo; which lower blood pressure by<br />relaxing the blood vessels.<br />&bull; Amlodipine belongs to a group of substances called &ldquo;calcium channel<br />blockers&rdquo;. Amlodipine stops calcium from moving into the blood vessel<br />wall which stops the blood vessels from tightening thereby also reducing<br />blood pressure.<br />The actions of both these substances contribute to stopping the tightening<br />of blood vessels, so that blood vessels relax and blood pressure decreases.<br />Olneda&trade; is used for the treatment of high blood pressure in patients whose<br />blood pressure is not controlled enough with either olmesartan medoxomil<br />or amlodipine alone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Olneda&trade;<br />&bull; if you are allergic to olmesartan medoxomil or to amlodipine or a special<br />group of calcium channel blockers, the dihydropyridines, or to any of the<br />other ingredients of this medicine (listed in section 6).<br />If you think you may be allergic, talk to your doctor before taking<br />Olneda&trade;.<br />&bull; if you are more than 3 months pregnant (It is also better to avoid<br />Olneda&trade; in early pregnancy - see section &ldquo;Pregnancy and breastfeeding&rdquo;.).<br />&bull; if you have diabetes or impaired kidney function and you are treated with<br />a blood pressure lowering medicine containing aliskiren.<br />&bull; if you have severe liver problems, if bile secretion is impaired or drainage<br />of bile from the gallbladder is blocked (e.g. by gallstones), or if you are<br />experiencing any jaundice (yellowing of the skin and eyes).<br />&bull; if you have very low blood pressure.<br />&bull; if you are suffering from insufficient blood supply to your tissues with<br />symptoms like e.g. low blood pressure, low pulse, fast heartbeat (shock,<br />including cardiogenic shock).<br />Cardiogenic shock means shock due to severe heart troubles.<br />&bull; if the blood flow from your heart is obstructed (e.g. because of the<br />narrowing of the aorta (aortic stenosis)).<br />&bull; if you suffer from low heart output (resulting in shortness of breath or<br />peripheral swellings) after a heart attack (acute myocardial infarction).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before using Olneda&trade;.<br />Tell your doctor if you are taking any of the following medicines used to<br />treat high blood pressure:<br />&bull; an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular<br />if you have diabetes-related kidney problems,<br />&bull; aliskiren.<br />Your doctor may check your kidney function, blood pressure, and the<br />amount of electrolytes (e.g. potassium) in your blood at regular intervals.<br />See also information under the heading &ldquo;Do not take Olneda&trade;&rdquo;.<br />Tell your doctor if you have any of the following health problems:<br />&bull; Kidney problems or a kidney transplant.<br />&bull; Liver disease.<br />&bull; Heart failure or problems with your heart valves or heart muscle.<br />&bull; Severe vomiting, diarrhoea, treatment with high doses of &ldquo;water tablets&rdquo;<br />(diuretics) or if you are on a low salt diet.<br />&bull; Increased levels of potassium in your blood.<br />&bull; Problems with your adrenal glands (hormone-producing glands on top of<br />the kidneys).<br />Contact your doctor if you experience diarrhoea that is severe, persistent<br />and causes substantial weight loss. Your doctor may evaluate your<br />symptoms and decide on how to continue your blood pressure medication.<br />As with any medicine which reduces blood pressure, an excessive drop in<br />blood pressure in patients with blood flow disturbances of the heart or brain<br />could lead to a heart attack or stroke. Your doctor will therefore check your<br />blood pressure carefully.<br />You must tell your doctor if you think that you are (or might become)<br />pregnant. Olneda&trade; is not recommended in early pregnancy, and must not<br />be taken if you are more than 3 months pregnant, as it may cause serious<br />harm to your baby if used at that stage (see section &ldquo;Pregnancy and<br />breast-feeding&rdquo;).<br />Children and adolescents (under 18)<br />Olneda&trade; is not recommended for children and adolescents under the age<br />of 18.<br />Other medicines and Olneda&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken or<br />might take any of the following medicines:<br />&bull; Other blood pressure lowering medicines, as the effect of Olneda&trade; can<br />be increased.<br />Your doctor may need to change your dose and/or to take other<br />precautions:<br />If you are taking an ACE-inhibitor or aliskiren (see also information under<br />the headings &ldquo;Do not take Olneda&trade; &rdquo; and &ldquo;Warnings and precautions&rdquo;).<br />&bull; Potassium supplements, salt substitutes containing potassium, &ldquo;water<br />tablets&rdquo; (diuretics) or heparin (for thinning the blood and prevention of<br />blood clots.). Using these medicines at the same time as Olneda&trade; may<br />raise the levels of potassium in your blood.<br />&bull; Lithium (a medicine used to treat mood swings and some types of<br />depression) used at the same time as Olneda&trade; may increase the toxicity of<br />lithium. If you have to take lithium, your doctor will measure your lithium<br />blood levels.<br />&bull; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs, medicines used to<br />relieve pain, swelling and other symptoms of inflammation, including<br />arthritis) used at the same time as Olneda&trade; may increase the risk of kidney<br />failure. The effect of Olneda&trade; can be decreased by NSAIDs.<br />&bull; Colesevelam hydrochloride, a drug that lowers the level of cholesterol in<br />your blood, as the effect of Olneda&trade; may be decreased. Your doctor may<br />advise you to take Olneda&trade; at least 4 hours before colesevelam<br />hydrochloride.<br />&bull; Certain antacids (indigestion or heartburn remedies), as the effect of<br />Olneda&trade; can be slightly decreased.<br />&bull; Medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir) or<br />for the treatment of fungal infections (e.g. ketoconazole, itraconazole).<br />&bull; Diltiazem, verapamil, (agents used for heart rhythm problems and high<br />blood pressure).<br />&bull; Rifampicin, erythromycin, clarithromycin (antibiotics), agents used<br />for tuberculosis or other infections.<br />&bull; St. John&rsquo;s wort (Hypericum perforatum), a herbal remedy.<br />&bull; Dantrolene (infusion for severe body temperature abnormalities).<br />&bull; Simvastatine, an agent used to lower levels of cholesterol and fats<br />(triglycerides) in the blood.<br />&bull; Tacrolimus, cyclosporine, used to control your body&rsquo;s immune response,<br />enabling your body to accept the transplanted organ.<br />Tell your doctor or pharmacist if you are taking, have recently taken or<br />might take any other medicines.<br />Olneda&trade; with food and drink<br />Olneda&trade; can be taken with or without food. Swallow the tablet with some<br />fluid (such as one glass of water). If possible, take your daily dose at the<br />same time each day, for example at breakfast time.<br />Grapefruit juice and grapefruit should not be consumed by people who are<br />taking Olneda&trade;. This is because grapefruit and grapefruit juice can lead to<br />an increase in the blood levels of the active ingredient amlodipine, which<br />can cause an unpredictable increase in the blood pressure lowering effect of<br />Olneda&trade;.<br />Elderly<br />If you are over 65 years of age, your doctor will regularly check your blood<br />pressure at any dose increase, to make sure that your blood pressure does<br />not become too low.<br />Black patients<br />As with other similar drugs the blood pressure lowering effect of<br />Olneda&trade; can be somewhat less in black patients<br />Pregnancy and breast-feeding<br />Pregnancy<br />You must tell your doctor if you think that you are (or might become)<br />pregnant. Your doctor will normally advise you to stop taking Olneda&trade;<br />before you become pregnant or as soon as you know you are pregnant and<br />will advise you to take another medicine instead of Olneda&trade;. Olneda&trade; is<br />not recommended in early pregnancy, and must not be taken when more<br />than 3 months pregnant, as it may cause serious harm to your baby if used<br />after the third month of pregnancy.<br />If you become pregnant during therapy with Olneda&trade;, please inform and<br />see your physician without delay.<br />Breast-feeding<br />Tell your doctor if you are breast-feeding or about to start breast-feeding.<br />Amlodipine has been shown to pass into breast milk in small amounts.<br />Olneda&trade; is not recommended for mothers who are breast-feeding, and<br />your doctor may choose another treatment for you if you wish to<br />breast-feed, especially if your baby is newborn, or was born prematurely.<br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor or pharmacist for advice before<br />taking this medicine.<br />Driving and using machines<br />You may feel sleepy, sick or dizzy or get a headache while being treated<br />for your high blood pressure. If this happens, do not drive or use machines<br />until the symptoms wear off. Ask your doctor for advice.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told<br />you. Check with your doctor or pharmacist if you are not sure.<br />&bull; The recommended dose of Olneda&trade; is one tablet per day.<br />&bull; The tablets can be taken with or without food. Swallow the tablet with<br />some fluid (such as a glass of water). The tablet should not be chewed. Do<br />not take them with grapefruit juice.<br />&bull; If possible, take your daily dose at the same time each day, for example at<br />breakfast time.<br />If you take more Olneda&trade; than you should<br />If you take more tablets than you should you may experience low blood<br />pressure with symptoms such as dizziness, fast or slow heart beat.<br />If you take more tablets than you should or if a child accidentally swallows<br />some, go to your doctor or nearest emergency department immediately and<br />take your medicine pack or this leaflet with you.<br />If you forget to take Olneda&trade;<br />If you forget to take a dose, take your normal dose on the following day as<br />usual. Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Olneda&trade;<br />It is important to continue to take Olneda&trade; unless your doctor tells you to<br />stop.<br />If you have any further questions on the use of this medicine, ask your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them. If they do occur, they are often mild and do not<br />require treatment to be stopped.<br />Although not many people may get them, the following two side effects<br />can be serious:<br />Allergic reactions, that may affect the whole body, with swelling of the<br />face, mouth and/or larynx (voice box) together with itching and rash may<br />occur during treatment with Olneda&trade;. If this happens stop taking<br />Olneda&trade; and talk to your doctor immediately.<br />Olneda&trade; can cause the blood pressure to fall too low in susceptible<br />individuals or as the result of an allergic reaction. This could cause severe<br />light-headedness or fainting. If this happens stop taking Olneda&trade;, talk<br />to your doctor immediately and lie down flat.<br />Other possible side effects with Olneda&trade;:<br />Common (may affect less than 1 in 10 people):<br />Dizziness; headache; swelling of ankles, feet, legs, hands, or arms;<br />tiredness.<br />Uncommon (may affect less than 1 in 100 people):<br />Dizziness on standing up; lack of energy; tingling or numbness of hands or<br />feet; vertigo; awareness of heart beat; fast heart beat; low blood pressure<br />with symptoms such as dizziness, light-headedness; difficult breathing;<br />cough; nausea; vomiting; indigestion; diarrhoea; constipation; dry mouth,<br />upper abdominal pain; skin rash; cramps; pain in arms and legs; back pain;<br />feeling more of an urge to pass urine; sexual inactivity; inability to get or<br />maintain an erection; weakness.<br />Some changes in blood test results have also been seen and include the<br />following: increased as well as decreased blood potassium levels,<br />increased blood creatinine levels, increased uric acid levels, increases in a<br />test of liver function (gamma glutamyl transferase levels).<br />Rare (may affect less than 1 in 1,000 people):<br />Drug hypersensitivity; fainting; redness and warm feeling of the face; red<br />itchy bumps (hives); swelling of face.<br />Side effects reported with use of olmesartan medoxomil or amlodipine<br />alone, but not with Olneda&trade; or in a higher frequency:<br />Olmesartan medoxomil<br />Common (may affect less than 1 in 10 people):<br />Bronchitis; sore throat; runny or stuffy nose; cough; abdominal pain;<br />stomach flu; diarrhoea; indigestion; nausea; pain in the joints or bones;<br />back pain; blood in the urine; infection of the urinary tract; chest pain;<br />flu-like symptoms; pain. Changes in blood test results as increased fat<br />levels (hypertriglyceridaemia), blood urea or uric acid increased and<br />increase in tests of liver and muscle function.<br />Uncommon (may affect less than 1 in 100 people):<br />Reduced number of a type of blood cells, known as platelets, which can<br />result in easily bruising or prolonged bleeding time; quick allergic<br />reactions that may affect the whole body and may cause breathing<br />problems as well as a rapid fall of blood pressure that may even lead to<br />fainting (anaphylactic reactions); angina (pain or uncomfortable feeling in<br />the chest, known as angina pectoris); itching; eruption of the skin; allergic<br />skin rash; rash with hives; swelling of the face; muscular pain; feeling<br />unwell.<br />Rare (may affect less than 1 in 1,000 people):<br />Swelling of the face, mouth and/or larynx (voice box); acute kidney failure<br />and kidney insufficiency; lethargy.<br />Amlodipine<br />Very common (may affect more than 1 in 10 people):<br />Oedema (fluid retention)<br />Common (may affect less than 1 in 10 people):<br />Abdominal pain; nausea; ankle swelling; feeling sleepy; redness and warm<br />feeling of the face, visual disturbance (including double vision and blurred<br />vision), awareness of heartbeat, diarrhoea, constipation, indigestion,<br />cramps, weakness, difficult breathing.<br />Uncommon (may affect less than 1 in 100 people):<br />Trouble sleeping; sleep disturbances; mood changes including feeling<br />anxious; depression; irritability; shiver; taste changes; fainting; ringing in<br />the ears (tinnitus); worsening of angina pectoris (pain or uncomfortable<br />feeling in the chest); irregular heartbeat; runny or stuffy nose; loss of hair;<br />purplish spots or patches on the skin due to small haemorrhages (purpura);<br />discoloration of the skin; excessive sweating; eruption of the skin; itching;<br />red itchy bumps (hives); pain of joints or muscles; problems to pass urine;<br />urge to pass urine at night; increased need to urinate (pass urine); breast<br />enlargement in men; chest pain; pain, feeling unwell; increase or decrease<br />in weight.<br />Rare (may affect less than 1 in 1,000 people):<br />Confusion<br />Very rare (may affect less than 1 in 10,000 people):<br />Reduction in the number of white cells in the blood, which could increase<br />the risk of infections; a reduction in the number of a type of blood cells<br />known as platelets, which can result in easily bruising or prolonged<br />bleeding time; increase in blood glucose; increased tightness of muscles or<br />increased resistance to passive movement (hypertonia); tingling or<br />numbness of hands or feet; heart attack; inflammation of blood vessels;<br />inflammation of the liver or the pancreas; inflammation of stomach lining;<br />thickening of gums; elevated liver enzymes; yellowing of the skin and<br />eyes; increased sensitivity of the skin to light; allergic reactions: itching,<br />rash, swelling of the face, mouth and/or larynx (voice box) together with<br />itching and rash, severe skin reactions including intense skin rash, hives,<br />reddening of the skin over your whole body, severe itching, blistering,<br />peeling and swelling of the skin, inflammation of mucous membranes<br />(Stevens Johnson Syndrome, toxic epidermal necrolysis), sometimes<br />life-threatening.<br />Not known (frequency cannot be estimated from the available data):<br />Trembling, rigid posture, mask-like face, slow movements and a shuffling,<br />unbalanced walk.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes<br />any possible side effects not listed in this leaflet. By reporting side effects<br />you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of reach and sight of children.<br />Do not store above 30 &ordm;C.<br />Do not use this medicine after the expiry date which is stated on the carton<br />and on the blister strip after &ldquo;EXP&rdquo;.<br />Do not throw away any medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Olneda&trade; contains<br />The active substances are olmesartan medoxomil and amlodipine<br />(as besilate).</p><p>40mg/10mg: Each film coated tablet contains 40 mg of Olmesartan<br />medoxomil and 10 mg of Amlodipine as Amlodipine Besilate.</p><p>40mg/10mg: Microcrystalline cellulose, Croscarmellose Sodium, colloidal<br />silicon dioxide, Anhydrous Lactose, Magnesium stearate, polyvinyl<br />alcohol, Polyethylene glycol, Titanium dioxide, Talc, Iron oxide red &amp;<br />Iron oxide Yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                40mg/10mg: Dark Brownish red colored, Round, Biconvex film coated
tablets with characteristic odor, debossed with ‘JP’ on one side and ‘168’
on other side.
40mg/10mg are available in a box of 3 blisters, 10 tablets per each blister.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer<br />Jamjoom Pharmaceuticals Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.<br />This leaflet was last reviewed in 06/2020; Version number 01</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">یحتوي أولنیدا على مادتین تسمي أولمیسارتان میدوكسومیل و أملودیبین (على ھیئة&nbsp;<br />أملودیبین بیسیلات). حیث تُساعد كلتا المادتین على التحكم في ارتفاع ضغط الدَّم.<br />&bull; تنتمي مادة أولمیسارتان میدوكسومیل إلى مجموعة من الأدویة تسمى &quot;مناھضات<br />مستقبلات الأنجیوتنسین ۲&quot; والتي تعمل على خفض ضغط الدم عن طریق إرخاء الأوعیة<br />الدمویة.<br />&bull; ینتمي أملودیبین إلى مجموعة من المواد تسمى &quot;حاصرات قنوات الكالسیوم&quot;. حیث تمنع<br />مادة الأملودیبین الكالسیوم من الانتقال إلى جدار الأوعیة الدمویة والذي بدوره یمنع الأوعیة<br />الدمویة من التضیق وبالتالي یخفض أیضًا ضغط الدم.<br />یساعد عمل كل من ھاتین المادتین على المساھمة في وقف تضیق الأوعیة الدمویة،<br />یُستخدم أولنیدا لعلاج ضغط الدم بحیث ترتخي الأوعیة الدمویة وینخفض ضغط الدم تباعًا<br />المرتفع في المرضى الذین یعانون من عدم التحكم في ضغط الدم بشكل كافِ من خلال<br />استخدام أولمیسارتان میدوكسومیل أو أملودیبین بشكل منفرد (كلٌّ دواء بمفرده).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>1.&nbsp; &nbsp;لا تتناول أولنیدا في الحالات الآتیة:<br />&bull; إذا كنت تعاني من حساسیة تجاه مادة أولمیسارتان میدوكسومیل أو مادة أملودیبین أو تجاه<br />مجموعة معینة من حاصرات قنوات الكالسیوم أو تجاه مركبات ثنائي ھیدرو البیریدین أو<br />تجاه أيٍّ مكون من المكونات الأخرى الداخلة في تركیب ھذا الدَّواء (المُدرجة في القسم رقم ٦).<br />استشر طبیبك قبل تناول أولنیدا إذا كنت تعتقد أنك تعاني من حساسیة تجاه أي مما سبق.<br />إذا كان حملكِ قد تجاوز أكثر من ۳ أشھر (فمن الأفضل تجنُّب تناوُل أولنیدا في مراحل&nbsp; الحمل المُبكرة انظري أیضًا القسم الخاص ب &quot;الحمل والرضاعة الطبیعیة&quot;).<br />&bull; إذا كنت مصابًا بداء السُّكَّري أو تُعاني من قصور في وظائف الكُلى، ویتم علاجك بدواء<br />خافض لضغط الدَّم یحتوي على ألیسكیرین.<br />&bull; إذا كنت تعاني من مشاكل شدیدة بالكبد ومن قصور في إفراز الصفراء أو لم یتم تصریف<br />العصارة الصفراویة من المرارة (بسبب حصى المرارة) أو إذا كنت تعاني من الیرقان<br />(اصفرار الجلد والعینین).<br />&bull; إذا كنت تعاني من انخفاض حادّ في ضغط الدم.<br />&bull; إذا كنت تعاني من نقص في ضخ الدم إلى الأنسجة مصحوب بأعراض مثل انخفاض ضغط<br />الدم، انخفاض النبض، سرعة ضربات القلب (صدمة بما في ذلك الصدمة القلبیة).<br />تعني الصدمة القلبیة حدوث سكتة بسبب اضطرابات شدیدة بالقلب.<br />&bull; إذا حدثت إعاقة لتدفق الدم من القلب (على سبیل المثال بسبب ضیق الصمام الأبھري<br />&quot;تضیّق الأبھر&quot;).<br />&bull; إذا كنت تعاني من انخفاض معدل نبضات القلب (مما یؤدي إلى حدوث ضیق في التنفس أو<br />أورام محیطیة) بعد الإصابة بنوبة قلبیة (انسداد حادّ في عضلة القلب).<br />تحذیرات واحتیاطات<br />تحدث إلى طبیبك أو الصیدلي قبل تناول أولنیدا<br />أخبر طبیبك إذا كنت تتناول أیًّا من الأدویة التَّالیة التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم:<br />&bull; مثبط الإنْزیم المُحَوِّل للأَنْجیُوتَنْسینِ (مثل إنالابریل، لیزینوبریل، رامیبریل)، على وجھ<br />الخصوص إذا كنت تُعاني من اضطرابات بالكُلى متعلقة بمرض السُّكَّري.<br />&bull; ألیسكیرین.<br />قد یقوم طبیبك بفحص وظائف الكُلى وضغط الدَّم وكمیة الكھارل (مثل: البوتاسیوم) في دمك<br />&nbsp;لا تتناول أولنیدا على فترات منتظمة. انظر أیضًا المعلومات المُدرجة تحت عنوان &quot;<br />أخبر طبیبك إذا كنت تعاني أيّ من المشاكل الصحیة الآتیة:<br />&bull; مشاكل بالكلى أو تم إجراء عملیة زرع كلى.<br />&bull; مرض كبدي.<br />&bull; فشل القلب أو مشاكل في صمامات القلب أو عضلات القلب.<br />&bull; قيء شدید أو إسھال أو علاج بجُرعات كبیرة من أقراص الماء (مدرّات البول) أو إذا كنت<br />تتبع نظام غذائي قلیل الملح.<br />&bull; زیادة نسبة البوتاسیوم في الدم.<br />&bull; مشاكل في الغدد الكظریة (الغدد المنتجة للھرمونات أعلى الكلى).<br />اتصل بطبیبك إذا كنت تعاني من إسھال شدید ومستمر والذي قد یسبب فقدانًا كبیرًا للوزن. قد<br />یقوم طبیبك بتقییم الأعراض واتخاذ قرار بشأن كیفیة متابعة علاج ضغط الدم. كما ھو الحال<br />مع أي دواء خافض لضغط الدم، فقد یؤدي الانخفاض الشدید في ضغط الدم لدى المرضى<br />الذین یعانون من اضطرابات في القلب أو الدماغ إلى حدوث نوبة قلبیة أو سكتة دماغیة. لذلك<br />سیقوم طبیبك بفحص ضغط الدَّم لدیك بعنایة.<br />یجب علیكِ إخبار طبیبكِ إذا كنتِ تعتقدین أنكِ حاملاً (أو قد تصبحین) حاملًا. فلا یوصى&nbsp;باستخدام أولنیدا<br />في بدایة الحمل ویجب ألا یتم تناولھ إذا تجاوز حملكِ الشھر الثالث حیث&nbsp;<br />إنھ قد یُسبب أضرارًا خطیرة لطفلكِ إذا تم استخدامھ في ھذه المرحلة (انظري القسم الخاص<br />ب &quot;الحمل والرَّضاعة الطبیعیة&quot;).<br />المرضى من الأطفال والمراھقین الذین تقل أعمارھم ۱۸ عامًا<br />لا یُوصى باستخدام أولنیدا في المرضى من الأطفال والمراھقین الذین تقل أعمارھم عن&nbsp;<br />۱۸ عامًا.<br />تناول أدویة أخرى مع أولنیدا<br />یُرجى إبلاغ طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّ من<br />الأدویة التالیة:<br />&nbsp;&bull; أدویة أخرى لخفض ضغط الدم، حیث أنھ یمكن زیادة تأثیر أولنیدا<br />قد یحتاج طبیبك إلى تغییر الجرعة الخاصة بك و/أو اتخاذ احتیاطات أخرى:<br />إذا كنت تتناول مثبط الإنْزیم المُحَوِّل للأَنْجیُوتَنْسینِ أو ألیسكیرین (انظر أیضًا المعلومات<br />في الحالات التالیة&quot; و&quot;تحذیرات واحتیاطات&quot;). &trade; الواردة أسفل العناوین &quot;لا تتناول أولنیدا<br />&bull; مكملات البوتاسیوم أو بدائل الملح التي تحتوي على البوتاسیوم &quot;أقراص الماء&quot; (مدرّات<br />البول) أو ھیبارین (دواء یستخدم لسیولة الدم وللوقایة من الجلطات الدمویة). حیث قد یؤدي<br />في نفس الوقت إلى رفع مستویات البوتاسیوم في الدم. &trade; استخدام ھذه الأدویة مع أولنیدا<br />&bull; لیثیوم (دواء یُستَخدَم لعلاج تقلبات المزاج وبعض أنواع الاكتئاب) حیث قد تزید سمیة&nbsp;اللیثیوم إذا استخدم في نفس وقت استخدام أولنیدا<br />إذا كان یجب علیك تناول اللیثیوم، فسوف<br />یقوم طبیبك بقیاس مستویات اللیثیوم في الدم.<br />الأدویة المضادة للالتھاب غیر الستیرویدیة التي تستخدم لتخفیف الألم &quot;NSAIDs&quot;) &bull;<br />والتورم وأعراض الالتھابات الأخرى بما في ذلك التھاب المفاصل) وقد تزید من خطر الفشل<br />&nbsp;كما یمكن أن ینخفض تأثیر أولنیدا .&trade; الكلوي إذا استخدمت في نفس الوقت مع أولنیدا<br />بواسطة الأدویة المضادة للالتھاب غیر الستیرویدیة.<br />&bull; كولیسیفیلام ھیدروكلورید وھو دواء یخفض مستوى الكولیسترول في الدم حیث قد یقلل<br />قد ینصحك طبیبك بتناول أولنیدا&nbsp; قبل تناول كولسیفلام ھیدروكلورید&nbsp;بأربع ( ٤) ساعات على الأقل.</p><p>2.&nbsp; &nbsp;من تأثیر أولنیدا<br /><br />&bull; مضادّات معینة لعلاج الحموضة (عسر الھضم أو علاجات حموضة المعدة) حیث قد تقلل<br />من تأثیر أولنیدا<br />&bull; الأدویة المستخدمة لفیروس نقص المناعة البشریة / الإیدز (مثل (ریتونافیر، اندینافیر،<br />نیلفینافیر) أو لعلاج الالتھابات الفطریّة (مثل كیتوكونازول، إیتراكونازول).<br />&bull; دیلتیازیم، فیرابامیل (أدویة تُستخدم لعلاج مشاكل اضطراب نظم القلب وضغط الدم<br />المرتفع).<br />&bull;أدویة تستخدم لعلاج<br />مرض السلّ أو أنواع أخرى من العدوى. ریفامبیسین، اریثرومیسین، كلاریثرومایسین (مضادات حیویة)،<br />&bull; نبتة سانت جونز (ھایبیریكم بیرفراتم)، دواء عشبي.<br />&bull; دانترولین (عقار للحقن التسریبي لعلاج اضطرابات درجة حرارة الجسم الشدیدة).<br />&bull; سیمفاستاتین، دواء یُستخدم لخفض مستویات الكولیسترول (الدھون الثلاثیة) في الدم.<br />&bull; أدویة تُستخدم للتحكم في استجابة الجسم المناعیة مما یسمح<br />للجسم بقبول العضو المزروع. تاكرولیموس، سیكلوسبورین،<br />یُرجى إبلاغ طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أیَّة أدویة<br />أخرى.<br />تناول أولنیدا مع الأطعمة والمشروبات&nbsp;<br />مع الطعام أو بدونھ. قم بابتلاع الأقراص مع بعض السوائل (مثل كوب &trade; یمكن تناول أولنیدا<br />واحد من الماء). وتناول الجرعة الخاصة بك من العقار، إن كان ذلك ممكناً، في نفس<br />الموعد من كل یوم؛ على سبیل المثال عند تناول الإفطار.<br />أن یشربوا عصیر جریب فروت أو أن یأكلوا ثمرة &trade; لا ینبغي للمرضى الذین یتناولون أولنیدا<br />الجریب فروت. وذلك لأن الجریب فروت وعصیر الجریب فروت یمكن أن یؤدي إلى زیادة<br />في مستویات المادة الفعالة أملودیبین في الدم مما قد یسبب زیادة غیر متوقعة في ضغط الدَّم؛<br />.&trade; وبالتالي یتم خفْض تأثیر أولنیدا<br />المرضى من كبار السن<br />إذا كان عمرك یزید عن ٦٥ عامًا، فسوف یقوم طبیبك بفحص ضغط الدم لدیك بانتظام عند<br />تناول أي جرعة زائدة، للتأكد من أن ضغط الدم لدیك لم ینخفض جداً.<br />المرضى أصحاب البشرة السمراء<br />على خفض ضغط الدم یكون &trade; كما ھو الحال مع العقاقیر المشابھة الأخرى، فإن تأثیر أولنیدا<br />أقل إلى حد ما لدى مرضى العرق الأسود.<br />الحَمْل والرضاعة الطبیعیة<br />الحَمْل<br />یجب علیكِ إخبار طبیبكِ إذا كنتِ تعتقدین أنكِ حاملاً (أو قد تصبحین) حاملًا. سینصحكِ<br />قبل أن تصبحي حاملاً أو بمجرد علمكِ بأنكِ حامل &trade; طبیبكِ عادةً بالتوقف عن تناول أولنیدا<br />في مراحل &trade; لا یُوصى باستخدام أولنیدا .&trade; وسینصحكِ بتناول دواء آخر بدلًا من أولنیدا<br />الحمل المبكرة ویجب ألا یتم تناوُلھ إذا تجاوز الحمل ثلاثة أشھر حیث أنھ قد یُسبب أضرارًا<br />خطیرة للجنین إذا تم استخدامھ بعد الشھر الثالث من الحمل.<br />&nbsp;یُرجى إبلاغ طبیبكِ والذھاب إلیھ دون تأخیر إذا أصبحتِ حاملاً أثناء العلاج بأولنیدا<br />الرَّضاعة الطبیعیة<br />أخبري طبیبكِ إذا كنتِ تُمارسین الرَّضاعة الطبیعیة أو على وشك البدء في ممارسة<br />الرَّضاعة الطبیعیة. فقد أثبتت الدراسات أن أملودیبین یفرز في لبن الأم بكمیات ضئیلة. لذا،<br />من جانب الأمھات اللواتي یمارسن الرضاعة الطبیعیة وقد یقرر &trade; لا یُوصي بتناول أولنیدا<br />طبیبكِ علاجًا آخر إذا كنتِ ترغبین في الإرضاع خاصة إذا كان طفلكِ حدیث الولادة أو ولد<br />قبل أوانھ. فإذا كُنتِ حاملًا أو تمارسین الرضاعة الطبیعیة، أو تعتقدین أنكِ حاملاً أو تخططین<br />لذلك، فاستشیري طبیبكِ أو الصیدليِ قبل تناوُل ھذا الدَّواء.<br />القیادة واستخدام الآلات<br />قد تشعر بنُعاس أو إعیاء أو دوار أو صداع أثناء فترة العلاج وذلك بسبب ارتفاع ضغط الدم<br />لدیك. إذا حدث ذلك، فتجنَّب القیادة أو استخدام الآلات حتى تزول ھذه الأعراض. ویُرجى<br />استشارة طبیبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا ھذا الدَّواء تمامًا حسب تعلیمات طبیبك أو الصیدلي. استشر طبیبك أو الصیدلي<br />إذا لم تكن متأكدًا من كیفیة التناول.<br />&bull; الجرعة المُوصى بھا من أولنیدا&nbsp;ھي قرص واحد یومیًّا.<br />&bull; یمكن تناول الأقراص مع الطعام أو بدونھ. قمْ بابتلاع الأقراص مع بعض السوائل (مثل<br />كوب واحد من الماء). یجب ألا یتم مضغ الأقراص. ولا تقمْ بتناول الأقراص مع عصیر<br />الجریب فروت.<br />&bull; یجب تناول الجرعة الخاصة بك من العقار، إن كان ذلك ممكنًا، في نفس الموعد من كل<br />یوم؛ على سبیل عند تناول الإفطار.<br />إذا تناولت كمیة أكثر مما یجب من أولنیدا<br />إذا تناولت كمیة أكثر مما یجب من الأقراص، فقد تعاني من انخفاض ضغط الدم مصحوب<br />بأعراض مثل دوخة أو سرعة أو تباطؤ نبضات القلب.<br />إذا تناولت كمیة أكثر مما یجب من الأقراص أو ابتلع أحد الأطفال بعض الأقراص عن<br />طریق الخطأ، یُرجي الذھاب إلى طبیبك أو التوجھ إلى أقرب قسم طوارئ على الفور وخذ<br />معك علبة الدواء أو نشرة الدواء.<br />&nbsp;إذا أغفلت تناول أولنیدا<br />إذا أغفلت تناول جرعة ما، قم بتناول الجرعة العادیة في الیوم التالي كالمعتاد. ولا تتناول<br />جرعة مضاعفة لتعویض جرعة أغفلتھا.<br />&nbsp;إذا توقفت عن تناول أولنیدا<br />من المھم الاستمرار في تناول أولنیدا ما لم یطلب منك طبیبك التوقف عن تناولھ. ،&trade;<br />إذا كانت لدیك أیّة أسئلة إضافیة حول استخدام ھذا الدَّواء، فاستشر طبیبك أو الصیدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;قد یُسبب ھذا الدَّواء، مثلھ مثل كافة الأدویة، تأثیراتٍ جانبیة على الرغم من عدم حدوثھا<br />لجمیع المرضى. وفي حالة حدوث مثل ھذه الآثار، فھي في أغلب الأحیان خفیفة ولا تحتاج<br />إلى إیقاف العلاج.<br />على الرغم من احتمال عدم حدوثھا لدى كثیر من المرضى، یمكن أن تكون ھاتین الحالتین<br />من الآثار الجانبیة التالیة خطیرة:<br />قد تحدث تفاعلات حساسیة تؤثر على الجسم كلھ مصحوبة بتورّم في الوجھ والفم و/أو<br />.&trade; الحنجرة (صندوق الصوت) إلى جانب وجود حكة وطفح جلدي أثناء فترة العلاج بأولنیدا<br />توقف عن تناول أولنیدا واستشر طبیبك على الفور إذا حدث لك ذلك. &trade;<br />یمكن أن یتسبب أولنیدا في انخفاض شدید في ضغط الدم لدي الأفراد المعرضین للإصابة &trade;<br />ویمكن أن یتسبب ذلك في حدوث دُوار أو إغماء. بھ أو كنتیجة لرد فعل تحسسي.<br />إذا حدث ذلك، توقف عن تناول أولنیدا واتصل بطبیبك على الفور وقمْ بالاستلقاء بشكل &trade;<br />مستوِ</p><p>&nbsp;آثار جانبیة مُحتملة بسبب تناول أولنیدا<br />آثار جانبیة شائعة (قد تؤثر على أقل من مریض واحد من بین كل ۱۰ مرضى).<br />دوخة، صداع، تورم الكاحلین أو القدمین أو الساقین أو الیدین أو الذراعین، شعور بالتعب.<br />آثار جانبیة غیر شائعة (قد تؤثر على أقل من مریض واحد من بین كل ۱۰۰ مریض)<br />دوخة عند الوقوف؛ نقص وفقدان طاقة الجسم (وھن)؛ شعور بوخز أو تخدّر في الیدین أو<br />القدمین؛ دُوار؛ إحساس بنبضات القلب؛ تسارع نبضات القلب؛ انخفاض ضغط الدم<br />مصحوبٍ بأعراض مثل دوخة ودوار؛ صعوبة في التنفس، سعال؛ غثیان؛ قيء؛ عسر<br />ھضم؛ إسھال؛ إمساك، جفاف الفم؛ ألم في الجزء العلوي من البطن؛ طفح جلدي؛ تشنجات،<br />ألم في الذراعین والساقین، ألم بالظھر؛ شعور برغبة شدیدة في التبول؛ برود جنسي؛ عدم<br />القدرة على الانتصاب أو الحفاظ على الانتصاب وضعف عام.<br />لوحظ بعض التغیرات في نتائج فحوصات الدم وتشمل ما یلي: زیادة وانخفاض مستویات<br />البوتاسیوم في الدم، زیادة مستویات الكریاتینین في الدم، زیادة مستویات حمض الیوریك<br />ونتائج مرتفعة في اختبار وظائف الكبد (مستویات ناقلات إنزیم جاما جلوتامیل).<br />آثار جانبیة نادرة (قد تُؤثر على أقل من مریض واحد من بین كل ۱٫۰۰۰ مریض)<br />فَرْطُ الحساسیة تجاه الدَّواء وإغماء واحمرار وشعور بحرارة الوجھ وبثور حمراء مثیرة<br />للحكة (شرى)، تورّم الوجھ.<br />تم الإبلاغ عن آثار جانبیة مع تناول أولمیسارتان میدوكسومیل أو أملودیبین بشكل منفرد<br />أو مع كثرة التكرار: &trade; (كل على حده)، ولكن لیس مع استخدام أولنیدا<br />أولمیسارتان میدوكسومیل<br />آثار جانبیة شائعة (قد تؤثر على أقل من مریض واحد من بین كل ۱۰ مرضى).<br />التھاب الشعب الھوائیة أو التھاب الحلق أو سیلان أو انسداد الأنف، سعال، ألم بالبطن،<br />انفلونزا المعدة، إِسْھال، عسر ھضم، غثیان، آلام في المفاصل أو العظام، ألم بالظھر، وجود<br />دم في البول، عدوى المسالك البولیة، ألم في الصدر، أعراض شبیھة بالأنفلونزا، ألم عام،<br />تغیرات في نتائج فحص الدم مثل زیادة مستویات الدھون (فرط ثلاثي جلسرید الدّم)،<br />ارتفاع یوریا الدم أو حمض الیوریك وزیادة في فحوصات وظائف الكبد والعضلات.<br />آثار جانبیة غیر شائعة (قد تؤثر على أقل من مریض واحد من بین كل ۱۰۰ مریض)<br />انخفاض عدد نوع ما من خلایا الدم المعروفة باسم الصفائح الدمویة، الذي یمكن أن یؤدي<br />إلى تكدُّم أو نزیف لفترة طویلة؛ تفاعلات حساسیة سریعة قد تؤثر على الجسم كلھ وقد<br />تسبب مشاكل في التنفس بالإضافة إلى حدوث ھبوط سریع في ضغط الدم قد یؤدي إلى<br />الإغماء (تفاعلات تأقیة)؛ ذبحة صدریة (ألم أو شعور بعدم الراحة في الصدر، فیما یعرف<br />بخُناق الصدر)، حكة؛ طفح جلدي؛ طفح جلدي تحسسي، طفح مصحوب ببثور (شَرَى)؛<br />تورّم في الوجھ؛ ألم بالعضلات وشعور عام بأنك لست على ما یُرام.<br />آثار جانبیة نادرة (قد تُؤثر على أقل من مریض واحد من بین كل ۱٫۰۰۰ مریض)<br />تورّم في الوجھ أو الفم و/أو الحنجرة (صندوق الصوت)، فشل كلوي حادّ وقصور كلوي،<br />خمول.<br />أملودیبین<br />آثار جانبیة شائعة جدًّا (قد تؤثر على أكثر من مریض واحد من بین كل ۱۰ مرضى):<br />وَذَمَة (احتباس السوائل)<br />آثار جانبیة شائعة (قد تؤثر على أقل من مریض واحد من بین كل ۱۰ مرضى).<br />ألم في البطن، غثیان، تورم الكاحل، شعور بالنعاس، احمرار وشعور بحرارة الوجھ،<br />اضطراب بصري (بما في ذلك ازدواج وعدم وضوح الرؤیة)، إحساس بنبضات القلب،<br />إسھال، إمساك، عسر ھضم، تشنجات، ضعف عام، صعوبة في التنفس.<br />آثار جانبیة غیر شائعة (قد تؤثر على أقل من مریض واحد من بین كل ۱۰۰ مریض)<br />مشاكل في النوم، اضطرابات بالنوم، تغیرات مزاجیة بما في ذلك شعور بالقلق، اكتئاب،<br />انفعال وعصبیة، شعور برعشة، تغیرات في حاسة التذوق، إغماء، رنین في الأذنین<br />(طنین)، تفاقم حالة الذبحة الصدریة (ألم أو شعور غیر مریح في الصدر)، عدم انتظام<br />ضربات القلب، سیلان أو انسداد الأنف، فقدان الشعر، بقع وعلامات أرجوانیة على الجلد<br />بسبب حدوث نزیف دموي صغیر (فُرْفُریّة أو ما یُعرف بالطفح الجلدي النزفي)، تغیر لون<br />الجلد، فرط التعرّق، طفح جلدي، حكة، نتوءات حاكّة حمراء (شَرَى)، آلام في المفاصل أو<br />العضلات، مشاكل في التبول، رغبة ملحة للتبول أثناء اللیل، زیادة الحاجة للتبول، تضخم<br />الثدي لدى المرضى من الرجال، ألم في الصدر، شعور بألم وعدم ارتیاح، زیادة أو نقصان<br />في الوزن.<br />آثار جانبیة نادرة (قد تُؤثر على أقل من مریض واحد من بین كل ۱٫۰۰۰ مریض)<br />شعور بالارتباك<br />آثار جانبیة نادرة جدًّا: (قد تُؤثر على أقل من مریض واحد من بین كل ۱۰٫۰۰۰<br />مریض):<br />انخفاض عدد الخلایا البیضاء في الدم مما قد یزید من خطر الإصابة بالعدوى، وانخفاض<br />في عدد خلایا الدم المعروفة باسم الصفائح الدمویة والذي یمكن أن یؤدي إلى حدوث كدمات<br />أو نزیف لفترة طویلة، زیادة نسبة الجلوكوز في الدم، زیادة شد العضلات أو زیادة المقاومة<br />للحركة السلبیة (فَرْطُ الضغط والتَّوَتُّر)، شعور بوخز أو تخدّر في الیدین أو القدمین، نوبة<br />قلبیة، التھاب في الأوعیة الدمویة، التھاب الكبد أو البنكریاس، التھاب في بطانة المعدة،<br />زیادة سمك اللثة، ارتفاع انزیمات الكبد، اصفرار الجلد والعینین، زیادة حساسیة الجلد تجاه<br />الضوء، ردود فعل تحسسیة، حكة، طفح جلدي، تورّم في الوجھ أو الفم و/أو الحنجرة<br />(صندوق الصوت) مصحوبِ بحكة وطفح جلدي، ردود فعل تحسسیة جلدیة شدیدة بما في<br />ذلك طفح جلدي شدید، شرى، احمرار جلد الجسم بأكملھ، حكة شدیدة، تّقرّح وتقشر وتورم<br />الجلد والتھاب الأغشیة المخاطیة (متلازمة ستیفنز جونسون ، انحلال البشرة السمّي) الذي<br />قد یكون مھددًا للحیاة في بعض الأحیان.<br />آثار جانبیة غیر معروف معدّل تكررھا (لا یمكن تقدیر معدل التكرار من واقع البیانات<br />المتاحة):<br />رعشة، وضعیة تصلب الجسم، وَجْھٌ شبیھ بالقناع، بطء الحركة، المشي بعدم اتزان وبخُطى<br />قصیرة وببطء.<br />الإبلاغ عن الآثار الجانبیة<br />إذا أصبت بأیَّة تأثیرات جانبیة، تحدَّث إلى طبیبك أو الصیدلي. یشمل ذلك أیّة تأثیرات<br />جانبیة مُحتمَلة غیر مُدرجة في ھذه النَّشرة. یمكنك المساعدة في توفیر معلومات إضافیة<br />حول أمان استخدام ھذا الدَّواء من خلال إبلاغك عن التأثیرات الجانبیة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">یُحفظ بعیدًا عن متناول و مرأى الأطفال.<br />یحفظ في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />لا تستعمل ھذا الدَّواء بعد انتھاء تاریخ الصلاحیة المدون على العبوة الكرتونیة والشریط<br />&quot; بعد كلمة&nbsp;.&quot;EXP<br />لا تتخلص من الأدویة عن طریق إلقائھا في میاه الصرف أو المخلفات المنزلیة. استشر<br />الصیدلي حول كیفیة التَّخلص من الأدویة التي لم تعد تستخدمھا. ستُساعد ھذه الإجراءات<br />في الحفاظ على البیئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المواد الفعّالة ھي أولمیسارتان میدوكسومیل وأملودیبین (على ھیئة أملودیبین بیسیلات).</p><p>٤۰ ملجم / ۱۰ ملجم: یحتوي كل قرص مغلف على من 40 ملجم أولمیسارتان<br />میدوكسومیل و ۱۰ ملجم من أملودیبین على ھیئة أملودیبین بیسیلات.</p><p>٤۰ ملجم/ ۱۰ ملجم: سلیلوز دقیق التَّبلور، كروسكارمیلوز الصودیوم، ثاني أكسید<br />السیلیكون الغروي، لاكتوز لامائي، ستیرات الماغنسیوم ، كحول بولي فینیل ، جلیكول<br />البولي إیثیلین ، ثاني أكسید التیتانیوم، تلك، أكسید الحدید الأحمر و أكسید الحدید الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>٤۰ ملجم/ ۱۰ ملجم: أقراص مغلفة ذات لون بني داكن، مستدیرة الشكل، محدّبة الوجھین،</p><p>.&quot; وعلى الجانب الآخر &quot; 168 &quot;JP&quot; ذات رائحة ممیزة، محفور على أحد جانبیھا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة مصنع جمجوم للأدویة،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />ھاتف: 608111-12-966+</p><p>فاكس: 6081222-12-966+<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />- المركز الوطني للتیقظ و السلامة الدوائیة</p><p>فاكس: 7662-205-11-966+<br />للإتصال بالإدارة التنفیذیة للتیقظ وإدارة الأزمات.&nbsp;</p><p>هاتف: 2038222-11-966+</p><p>تحويلة: 2317-2356-2340<br />الخط الساخن للإبلاغ: ۱۹۹۹۹&nbsp;<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الإلكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06-2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Olneda 40 mg / 10 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                40mg/10mg: Each film coated tablet contains 40 mg of Olmesartan medoxomil and 10 mg of
Amlodipine as Amlodipine Besilate.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                40mg/10mg: Dark Brownish red colored, Round, Biconvex film coated tablets with
characteristic odor, debossed with ‘JP’ on one side and ‘168’ on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.<br />Olneda is indicated in adult patients whose blood pressure is not adequately controlled on<br />olmesartan medoxomil or amlodipine monotherapy (see section 4.2 and section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults<br />The recommended dosage of Olnedais 1 tablet per day.<br />Olneda 20 mg/5 mg may be administered in patients whose blood pressure is not adequately<br />controlled by 20 mg olmesartan medoxomil or 5 mg amlodipine alone.<br />Olneda 40 mg/5 mg may be administered in patients whose blood pressure is not adequately<br />controlled by Olneda 20 mg/5 mg.<br />Olneda 40 mg/10 mg may be administered in patients whose blood pressure is not adequately<br />controlled by Olneda 40 mg/5 mg<br />Olneda 40 mg/20 mg may be administered in patients whose blood pressure is not adequately<br />controlled by Olneda 40 mg/10 mg<br />A step-wise titration of the dosage of the individual components is recommended before changing<br />to the fixed combination. When clinically appropriate, direct change from monotherapy to the<br />fixed combination may be considered.</p><p>&nbsp;</p><p>For convenience, patients receiving olmesartan medoxomil and amlodipine from separate tablets<br />may be switched to Olneda tablets containing the same component doses.<br />Olneda can be taken with or without food.<br />Elderly (age 65 years or over)<br />No adjustment of the recommended dose is generally required for elderly people but increase of<br />the dosage should take place with care (see sections 4.4 and 5.2).<br />If up-titration to the maximum dose of 40 mg olmesartan medoxomil daily is required, blood<br />pressure should be closely monitored.<br />Renal impairment<br />The maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment<br />(creatinine clearance of 20 &ndash; 60 mL/min) is 20 mg olmesartan medoxomil once daily, owing to<br />limited experience of higher dosages in this patient group. The use of Olneda in patients with<br />severe renal impairment (creatinine clearance &lt; 20 mL/min) is not recommended (see 4.4, 5.2).<br />Monitoring of potassium levels and creatinine is advised in patients with moderate renal<br />impairment.<br />Hepatic impairment<br />Olnedashould be used with caution in patients with mild to moderate hepatic impairment (see<br />sections 4.4, 5.2).<br />In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once<br />daily is recommended and the maximum dose should not exceed 20 mg once daily. Close<br />monitoring of blood pressure and renal function is advised in hepatically-impaired patients who&nbsp;are already receiving diuretics and/or other antihypertensive agents. There is no experience of<br />olmesartan medoxomil in patients with severe hepatic impairment.<br />As with all calcium antagonists, amlodipine&#39;s half-life is prolonged in patients with impaired liver<br />function and dosage recommendations have not been established. Olneda should therefore be<br />administered with caution in these patients. The pharmacokinetics of amlodipine have not been<br />studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated<br />slowly in patients with impaired liver function. Use of Olneda in patients with severe hepatic<br />impairment is contraindicated (see section 4.3).<br />Paediatric population<br />The safety and efficacy of Olneda in children and adolescents below 18 years has not been<br />established. No data are available.<br />Method of administration:<br />The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water). The<br />tablet should not be chewed and should be taken at the same time each day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to dihydropyridine derivatives or to any of the excipients
listed in section 6.1.
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
Severe hepatic insufficiency and biliary obstruction (see section 5.2).
The concomitant use of Olneda with aliskiren-containing products is contraindicated in patients
with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see sections 4.5 and 5.1).
Due to the component amlodipine Olneda is also contraindicated in patients with:
- severe hypotension.
- shock (including cardiogenic shock).
- obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis).
- haemodynamically unstable heart failure after acute myocardial infarction.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients with hypovolaemia or sodium depletion:<br />Symptomatic hypotension may occur in patients who are volume and/or sodium depleted by<br />vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting, especially after the first<br />dose. Correction of this condition prior to administration of Olneda or close medical supervision<br />at the start of the treatment is recommended.<br />Other conditions with stimulation of the renin-angiotensin-aldosterone system:<br />In patients whose vascular tone and renal function depend predominantly on the activity of the<br />renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or<br />underlying renal disease, including renal artery stenosis), treatment with other medicinal products<br />that affect this system, such as angiotensin II receptor antagonists, has been associated with acute<br />hypotension, azotaemia, oliguria or, rarely, acute renal failure.<br />Renovascular hypertension:<br />There is an increased risk of severe hypotension and renal insufficiency when patients with<br />bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated<br />with medicinal products that affect the renin-angiotensin-aldosterone system.<br />Renal impairment and kidney transplantation:<br />When Olneda is used in patients with impaired renal function, periodic monitoring of serum<br />potassium and creatinine levels is recommended. Use of Olneda is not recommended in patients</p><p>with severe renal impairment (creatinine clearance &lt; 20 mL/min) (see sections 4.2, 5.2). There is<br />no experience of the administration of Olneda in patients with a recent kidney transplant or in<br />patients with end-stage renal impairment (i.e. creatinine clearance &lt; 12 mL/min).<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS):<br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or<br />aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including<br />acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors,<br />angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and<br />5.1).<br />If dual blockade therapy is considered absolutely necessary, this should only occur under specialist<br />supervision and subject to frequent close monitoring of renal function, electrolytes and blood<br />pressure.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients<br />with diabetic nephropathy.<br />Hepatic impairment:<br />Exposure to amlodipine and olmesartan medoxomil is increased in patients with hepatic<br />impairment (see section 5.2). Care should be taken when Olneda is administered in patients with<br />mild to moderate hepatic impairment. In moderately impaired patients, the dose of olmesartan<br />medoxomil should not exceed 20 mg (see section 4.2). In patients with impaired hepatic function,<br />amlodipine should be initiated at the lower end of the dosing range and caution should be used,<br />both on initial treatment and when increasing the dose. Use of Olneda in patients with severe<br />hepatic impairment is contraindicated (see section 4.3).</p><p>Hyperkalaemia:<br />As with other angiotensin II antagonists and ACE inhibitors, hyperkalaemia may occur during<br />treatment, especially in the presence of renal impairment and/or heart failure (see section 4.5).<br />Close monitoring of serum potassium levels in at-risk patients is recommended.<br />Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes<br />containing potassium, or other medicinal products that may increase potassium levels (heparin,<br />etc.) should be undertaken with caution and with frequent monitoring of potassium levels.<br />Lithium:<br />As with other angiotensin II receptor antagonists, the concomitant use of Olneda and lithium is not<br />recommended (see section 4.5).<br />Aortic or mitral valve stenosis; obstructive hypertrophic cardiomyopathy:<br />Due to the amlodipine component of Olneda, as with all other vasodilators, special caution is<br />indicated in patients suffering from aortic or mitral valve stenosis, or obstructive hypertrophic<br />cardiomyopathy.<br />Primary aldosteronism:<br />Patients with primary aldosteronism generally will not respond to antihypertensive medicinal<br />products acting through inhibition of the renin-angiotensin system. Therefore, the use of Olneda<br />is not recommended in such patients.</p><p>Heart failure:<br />As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal<br />function may be anticipated in susceptible individuals. In patients with severe heart failure whose<br />renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment<br />with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has<br />been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure<br />and/or death.<br />Patients with heart failure should be treated with caution. In a long-term, placebo controlled study<br />of amlodipine in patients with severe heart failure (NYHA III and IV), the reported incidence of<br />pulmonary oedema was higher in the amlodipine group than in the placebo group (see section 5.1).<br />Calcium channel blockers, including amlodipine, should be used with caution in patients with<br />congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.<br />Sprue-like enteropathy:<br />In very rare cases severe, chronic diarrhoea with substantial weight loss has been reported in<br />patients taking olmesartan few months to years after drug initiation, possibly caused by a localized<br />delayed hypersensitivity reaction. Intestinal biopsies of patients often demonstrated villous<br />atrophy. If a patient develops these symptoms during treatment with olmesartan, and in the absence<br />of other apparent etiologies, olmesartan treatment should be immediately discontinued and should<br />not be restarted. If diarrhoea does not improve during the week after the discontinuation, further<br />specialist (e.g. a gastro-enterologist) advice should be considered.<br />Ethnic differences:<br />As with all other angiotensin II antagonists, the blood pressure lowering effect of Olneda can be<br />somewhat less in black patients than in non-black patients, possibly because of a higher prevalence<br />of low-renin status in the black hypertensive population.</p><p>Elderly:<br />In the elderly, increase of the dosage should take place with care (see section 5.2).<br />Pregnancy:<br />Angiotensin II antagonists should not be initiated during pregnancy. Unless continued angiotensin<br />II antagonist therapy is considered essential, patients planning pregnancy should be changed to<br />alternative antihypertensive treatments which have an established safety profile for use in<br />pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should be<br />stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3<br />and 4.6).<br />Other:<br />As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic<br />heart disease or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.<br />This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say<br />essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Potential interactions related to the Olneda combination:<br />To be taken into account with concomitant use<br />Other antihypertensive agents:<br />The blood pressure lowering effect of Olneda can be increased by concomitant use of other<br />antihypertensive medicinal products (e.g. alpha blockers, diuretics).<br />Potential interactions related to the olmesartan medoxomil component of Olneda:<br />Concomitant use not recommended&nbsp;ACE-inhibitors, angiotensin II receptor blockers or aliskiren:<br />Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system<br />(RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren<br />is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and<br />decreased renal function (including acute renal failure) compared to the use of a single RAASacting<br />agent (see sections 4.3, 4.4 and 5.1).<br />Medicinal products affecting potassium levels:<br />Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes<br />containing potassium or other medicinal products that may increase serum potassium levels (e.g.<br />heparin, ACE inhibitors) may lead to increases in serum potassium (see section 4.4). If medicinal<br />products which affect potassium levels are to be prescribed in combination with Olneda,<br />monitoring of serum potassium levels is recommended.<br />Lithium:<br />Reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with angiotensin converting enzyme inhibitors and, rarely,<br />with angiotensin II antagonists. Therefore concomitant use of Olneda and lithium is not<br />recommended (see section 4.4). If concomitant use of Olneda and lithium proves necessary, careful<br />monitoring of serum lithium levels is recommended.<br />Concomitant use requiring caution<br />Non-steroidal anti-inflammatory medicinal products (NSAIDs) including selective COX-2<br />inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs:<br />When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the<br />antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and&nbsp;NSAIDs may increase the risk of worsening of renal function and may lead to an increase in serum<br />potassium. Therefore monitoring of renal function at the beginning of such concomitant therapy<br />is recommended, as well as adequate hydration of the patient.<br />Bile acid sequestering agent colesevelam:<br />Concurrent administration of the bile acid sequestering agent colesevelam hydrochloride reduces<br />the systemic exposure and peak plasma concentration of olmesartan and reduces t1/2.<br />Administration of olmesartan medoxomil at least 4 hours prior to colesevelam hydrochloride<br />decreased the drug interaction effect. Administering olmesartan medoxomil at least 4 hours before<br />the colesevelam hydrochloride dose should be considered (see section 5.2).<br />Additional information<br />After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in<br />bioavailability of olmesartan was observed.<br />Olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics<br />of warfarin or the pharmacokinetics of digoxin. Coadministration of olmesartan medoxomil with<br />pravastatin had no clinically relevant effects on the pharmacokinetics of either component in<br />healthy subjects.<br />Olmesartan had no clinically relevant inhibitory effects on human cytochrome P450 enzymes<br />1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4 in vitro, and had no or minimal inducing effects on<br />rat cytochrome P450 activities. No clinically relevant interactions between olmesartan and<br />medicinal products metabolised by the above cytochrome P450 enzymes are expected.</p><p>Potential interactions related to the amlodipine component of Olneda:<br />Effects of other medicinal products on amlodipine<br />CYP3A4 inhibitors:<br />Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors,<br />azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may<br />give rise to significant increase in amlodipine exposure. The clinical translation of these PK<br />variations may be more pronounced in the elderly. There is an increased risk of hypotension. Close<br />observation of patients is recommended and dose adjustment may thus be required.<br />CYP3A4 inducers:<br />Upon co-administration of known inducers of the CYP3A4, the plasma concentration of<br />amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation<br />considered both during and after concomitant medication particularly with strong CYP3A4<br />inducers (e.g. rifampicin, hypericum perforatum).<br />Administration of amlodipine with grapefruit or grapefruit juice is not recommended as<br />bioavailability may be increased in some patients resulting in increased blood pressure lowering<br />effects.<br />Dantrolene (infusion): In animals, lethal ventricular fibrillation and cardiovascular collapse are<br />observed in association with hyperkalaemia after administration of verapamil and intravenous<br />dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium<br />channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia<br />and in the management of malignant hyperthermia.<br />Effects of amlodipine on other medicinal products<br />The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of<br />other antihypertensive agents.</p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin,<br />digoxin or warfarin.<br />Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin<br />resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the<br />dose of simvastatin in patients on amlodipine to 20 mg daily.<br />Tacrolimus: There is a risk of increased tacrolimus blood levels when co-administered with<br />amlodipine. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient<br />treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of<br />tacrolimus when appropriate.<br />Cyclosporine: In a prospective study in renal transplant patients, an average 40% increase in trough<br />cyclosporine levels was observed when used concomitantly with amlodipine. The coadministration<br />of Olneda with cyclosporine may increase exposure to cyclosporine. Monitor<br />trough cyclosporine levels during concomitant use and cyclosporine dose reductions should be<br />made as necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data about the use of Olneda in pregnant patients. Animal reproductive toxicity<br />studies with Olneda have not been performed.<br />Olmesartan medoxomil (active ingredient of Olneda)<br />The use of angiotensin II antagonists is not recommended during the first trimester of pregnancy<br />(see section 4.4). The use of angiotensin II antagonists is contraindicated during the 2nd and 3rd<br />trimesters of pregnancy (see sections 4.3 and 4.4).<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE<br />inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase<br />in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with<br />angiotensin II antagonists, similar risks may exist for this class of drugs. Unless continued</p><p>angiotensin II antagonists therapy is considered essential, patients planning pregnancy should be<br />changed to alternative anti-hypertensive treatments which have an established safety profile for<br />use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should<br />be stopped immediately, and, if appropriate, alternative therapy should be started.<br />Exposure to angiotensin II antagonists therapy during the second and third trimesters is known to<br />induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification<br />retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<br />Should exposure to angiotensin II antagonists have occurred from the second trimester on,<br />ultrasound check of renal function and skull is recommended. Infants whose mothers have taken<br />angiotensin II antagonists should be closely observed for hypotension (see sections 4.3 and 4.4).<br />Amlodipine (active ingredient of Olneda)<br />Data on a limited number of exposed pregnancies do not indicate that amlodipine or other calcium<br />receptor antagonists have a harmful effect on the health of the fetus. However, there may be a risk<br />of prolonged delivery.<br />As a consequence, Olneda is not recommended during the first trimester of pregnancy and is<br />contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).<br />Breastfeeding<br />Olmesartan is excreted into the milk of lactating rats. However, it is not known whether olmesartan<br />passes into human milk.<br />Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant<br />has been estimated with an interquartile range of 3 - 7%, with a maximum of 15%. The effect of<br />amlodipine on infants is unknown.<br />During breast-feeding, Olneda is not recommended and alternative treatments with better<br />established safety profiles during breast-feeding are preferable, especially while nursing a new<br />born or preterm infant.</p><p>Fertility<br />Reversible biochemical changes in the head of spermatozoa have been reported in some patients<br />treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of<br />amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section<br />5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Olneda can have minor or moderate influence on the ability to drive and use machines.<br />Dizziness, headache, nausea or fatigue may occasionally occur in patients taking antihypertensive<br />therapy, which may impair the ability to react. Caution is recommended especially at the start of<br />treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Very rare (&lt;1/10,000), not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="2"><p>MedDRA System Organ Class</p></td><td colspan="" rowspan="2"><p>Adverse reactions</p></td><td colspan="" rowspan=""><p>Frequency</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Olmesartan/Amlodipine combination</p></td><td colspan="" rowspan=""><p>Olmesartan</p></td><td colspan="" rowspan=""><p>Amlodipine</p></td></tr><tr><td colspan="" rowspan="2"><p>Blood and lymphatic system disorders</p></td><td colspan="" rowspan=""><p>Leukocytopenia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Thrombocytopenia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan="2"><p>Immune system disorders</p></td><td colspan="" rowspan=""><p>Allergic reaction /Drug hypersensitivity</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Anaphylactic reaction</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="4"><p>Metabolism and nutrition disorders</p></td><td colspan="" rowspan=""><p>Hyperglycaemia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Hyperkalaemia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Hypertriglyceridaemia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Hyperuricaemia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="6"><p>Psychiatric disorders</p></td><td colspan="" rowspan=""><p>Confusion</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Rare</p></td></tr><tr><td colspan="" rowspan=""><p>Depression</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Insomnia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Irritability</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Libido decreased</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Mood changes (including anxiety)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan="14"><p>Nervous system disorders</p></td><td colspan="" rowspan=""><p>Dizziness</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Dysgeusia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Headache</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common (especially at the beginning of treatment)</p></td></tr><tr><td colspan="" rowspan=""><p>Hypertonia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Hypoaesthesia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Lethargy</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Paraesthesia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Peripheral neuropathy</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Postural dizziness</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Sleep disorder</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Somnolence</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Syncope</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Tremor</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Extrapyramidal disorder</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Eye disorders</p></td><td colspan="" rowspan=""><p>Visual disturbance (including diplopia)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan="2"><p>Ear and labyrinth disorders</p></td><td colspan="" rowspan=""><p>Tinnitus</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Vertigo</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="5"><p>Cardiac disorders</p></td><td colspan="" rowspan=""><p>Angina pectoris</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon (incl. aggravation of angina pectoris)</p></td></tr><tr><td colspan="" rowspan=""><p>Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Myocardial infarction</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Palpitations</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Tachycardia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="4"><p>Vascular disorders</p></td><td colspan="" rowspan=""><p>Hypotension</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Orthostatic hypotension</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Flushing</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Vasculitis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan="5"><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="" rowspan=""><p>Bronchitis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Cough</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Dyspnoea</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Pharyngitis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Rhinitis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan="14"><p>Gastrointestinal disorders</p></td><td colspan="" rowspan=""><p>Abdominal pain</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Altered bowel habits (including diarrhoea and constipation)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Constipation</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Diarrhoea</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Dry mouth</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Dyspepsia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Gastritis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Gastroenteritis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Gingival hyperplasia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Nausea</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Pancreatitis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Upper abdominal pain</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Vomiting</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Sprue-like enteropathy (see section 4.4)</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="3"><p>Hepato-biliary disorders</p></td><td colspan="" rowspan=""><p>Hepatic enzymes increased</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Very rare (mostly consistent with cholestasis)</p></td></tr><tr><td colspan="" rowspan=""><p>Hepatitis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Jaundice</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan="16"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="" rowspan=""><p>Alopecia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Angioneurotic oedema</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Allergic dermatitis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Erythema multiforme</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Exanthema</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Exfoliative dermatitis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Hyperhydrosis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Photosensitivity</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Pruritus</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Purpura</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Quincke oedema</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Rash</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Skin discoloration</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Stevens-Johnson syndrome</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very rare</p></td></tr><tr><td colspan="" rowspan=""><p>Toxic Epidermal Necrolysis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Urticaria</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan="8"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="" rowspan=""><p>Ankle swelling</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Arthralgia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Arthritis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Back pain</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Muscle spasm</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Myalgia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Pain in extremity</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Skeletal pain</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="8"><p>Renal and urinary disorders</p></td><td colspan="" rowspan=""><p>Acute renal failure</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Haematuria</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Increased urinary frequency</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Micturition disorder</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Nocturia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Pollakiuria</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Renal insufficiency</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Urinary tract infection</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="2"><p>Reproductive system and breast disorders</p></td><td colspan="" rowspan=""><p>Erectile dysfunction/impotence</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Gynecomastia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan="11"><p>General disorders and administration site conditions</p></td><td colspan="" rowspan=""><p>Asthenia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Chest pain</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Face oedema</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Fatigue</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td></tr><tr><td colspan="" rowspan=""><p>Influenza-like symptoms</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Lethargy</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Malaise</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Oedema</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Very common</p></td></tr><tr><td colspan="" rowspan=""><p>Pain</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Peripheral oedema</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Pitting oedema</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan="8"><p>Investigations</p></td><td colspan="" rowspan=""><p>Blood creatinine increased</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Blood creatine phosphokinase increased</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Blood potassium decreased</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Blood urea increased</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Blood uric acid increased</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Gamma glutamyl transferase increased</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>Weight decrease</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Weight increase</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr></tbody></table><p>Single cases of rhabdomyolysis have been reported in temporal association with the intake of<br />angiotensin II receptor blockers. Single cases of extrapyramidal syndrome have been reported in<br />patients treated with amlodipine.<br />To reports any side effect(s):<br /> Saudi Arabia<br />-The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317--2356-2340.<br />Toll free phone: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms:<br />There is no experience of overdose with Olneda. The most likely effects of olmesartan medoxomil<br />overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic<br />(vagal) stimulation occurred. Amlodipine overdosage can be expected to lead to excessive<br />peripheral vasodilatation with marked hypotension and possibly a reflex tachycardia. Marked and<br />potentially prolonged systemic hypotension up to and including shock with fatal outcome has been<br />reported.<br />Treatment:<br />If intake is recent, gastric lavage may be considered. In healthy subjects, the administration of<br />activated charcoal immediately or up to 2 hours after ingestion of amlodipine has been shown to<br />reduce substantially the absorption of amlodipine.<br />Clinically significant hypotension due to an overdose of Olnedarequires active support of the<br />cardiovascular system, including close monitoring of heart and lung function, elevation of the<br />extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be<br />helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to<br />its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium<br />channel blockade. Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.<br />The dialysability of olmesartan is unknown.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists and calcium channel blockers,<br />ATC code C09DB02.<br />Mechanism of action<br />Olneda is a combination of an angiotensin II receptor antagonist, olmesartan medoxomil, and a<br />calcium channel blocker, amlodipine besilate. The combination of these active ingredients has an<br />additive antihypertensive effect, reducing blood pressure to a greater degree than either component<br />alone.<br />Clinical efficacy and safety<br />Olneda<br />In an 8-week, double-blind, randomised, placebo-controlled factorial design study in 1940 patients<br />(71% Caucasian and 29% non-Caucasian patients), treatment with each combination dose of<br />Olnedaresulted in significantly greater reductions in diastolic and systolic blood pressures than the<br />respective monotherapy components. The mean change in systolic/diastolic blood pressure was<br />dose-dependent: -24/-14 mmHg (20 mg/5 mg combination), -25/-16 mmHg (40 mg/5 mg<br />combination) and -30/-19 mmHg (40 mg/10 mg combination).<br />Olneda40 mg/5 mg reduced seated systolic/diastolic blood pressure by an additional 2.5/1.7 mmHg<br />over Olneda20 mg/5 mg. Similarly Olneda40 mg/10 mg reduced seated systolic/diastolic blood<br />pressure by an additional 4.7/3.5 mmHg over Olneda40 mg/5 mg.<br />The proportions of patients reaching blood pressure goal (&lt; 140/90 mmHg for non-diabetic<br />patients and &lt; 130/80 mmHg for diabetic patients) were 42.5%, 51.0% and 49.1% for Olneda20<br />mg/5 mg, 40 mg/5 mg and 40 mg/10 mg respectively.<br />The majority of the antihypertensive effect of Olneda was generally achieved within the first 2<br />weeks of therapy.</p><p>A second double-blind, randomised, placebo-controlled study evaluated the effectiveness of<br />adding amlodipine to the treatment in Caucasian patients whose blood pressure was inadequately<br />controlled by 8 weeks of monotherapy with 20 mg olmesartan medoxomil.<br />In patients who continued to receive only 20 mg olmesartan medoxomil, systolic/diastolic blood<br />pressure was reduced by -10.6/ -7.8 mmHg after a further 8 weeks. The addition of 5 mg<br />amlodipine for 8 weeks resulted in a reduction in systolic/diastolic blood pressure of -16.2/-10.6<br />mmHg (p = 0.0006).<br />The proportion of patients reaching blood pressure goal (&lt; 140/90 mmHg for non-diabetic patients<br />and &lt; 130/80 mmHg for diabetic patients) was 44.5% for the 20 mg/5 mg combination compared<br />to 28.5% for 20 mg olmesartan medoxomil.<br />A further study evaluated the addition of various doses of olmesartan medoxomil in Caucasian<br />patients whose blood pressure was not adequately controlled by 8 weeks of monotherapy with 5<br />mg amlodipine.<br />In patients who continued to receive only 5 mg amlodipine, systolic/diastolic blood pressure was<br />reduced by -9.9/ -5.7 mmHg after a further 8 weeks. The addition of 20 mg olmesartan medoxomil<br />resulted in a reduction in systolic/diastolic blood pressure of -15.3/-9.3 mmHg and the addition of<br />40 mg olmesartan medoxomil resulted in a reduction in systolic/diastolic blood pressure of -16.7/-<br />9.5 mmHg (p &lt; 0.0001).<br />The proportions of patients reaching blood pressure goal (&lt; 140/90 mmHg for non-diabetic<br />patients and &lt; 130/80 mmHg for diabetic patients) was 29.9% for the group who continued to<br />receive 5 mg amlodipine alone, 53.5% for Olneda20 mg/5 mg and 50.5% for Olneda40 mg/5 mg.<br />Randomised data in uncontrolled hypertensive patients, comparing the use of medium dose Olneda<br />combination therapy versus escalation to top dose monotherapy of amlodipine or olmesartan, are<br />not available.<br />The three studies performed confirmed that the blood pressure lowering effect of Olneda once<br />daily was maintained throughout the 24-hour dose interval, with trough-to-peak ratios of 71% to&nbsp;82% for systolic and diastolic response and with 24-hour effectiveness being confirmed by<br />ambulatory blood pressure monitoring.<br />The antihypertensive effect of Olneda was similar irrespective of age and gender, and was similar<br />in patients with and without diabetes.<br />In two open-label, non-randomised extension studies, sustained efficacy using Olneda40 mg/5 mg<br />was demonstrated at one year for 49 - 67% of patients.<br />Olmesartan medoxomil (active ingredient of Olneda)<br />The olmesartan medoxomil component of Olnedais a selective angiotensin II type 1 (AT1) receptor<br />antagonist. Olmesartan medoxomil is rapidly converted to the pharmacologically active<br />metabolite, olmesartan. Angiotensin II is the primary vasoactive hormone of the renin-angiotensinaldosterone<br />system and plays a significant role in the pathophysiology of hypertension. The effects<br />of angiotensin II include vasoconstriction, stimulation of the synthesis and release of aldosterone,<br />cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor and<br />aldosterone-secreting effects of angiotensin II by blocking its binding to the AT1 receptor in<br />tissues including vascular smooth muscle and the adrenal gland. The action of olmesartan is<br />independent of the source or route of synthesis of angiotensin II. The selective antagonism of the<br />angiotensin II (AT1) receptors by olmesartan results in increases in plasma renin levels and<br />angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.<br />In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial<br />blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during<br />long-term treatment, or of rebound hypertension after abrupt cessation of therapy.<br />Following once daily administration to patients with hypertension, olmesartan medoxomil<br />produces an effective and smooth reduction in blood pressure over the 24 hour dose interval. Once<br />daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total<br />daily dose.</p><p>With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after<br />the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is<br />already observed after 2 weeks of treatment.<br />The effect of olmesartan medoxomil on mortality and morbidity is not yet known.<br />The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study in<br />4447 patients with type 2 diabetes, normo-albuminuria and at least one additional cardiovascular<br />risk factor, investigated whether treatment with olmesartan could delay the onset of<br />microalbuminuria. During the median follow-up duration of 3.2 years, patients received either<br />olmesartan or placebo in addition to other antihypertensive agents, except ACE inhibitors or<br />ARBs.<br />For the primary endpoint, the study demonstrated a significant risk reduction in the time to onset<br />of microalbuminuria, in favour of olmesartan. After adjustment for BP differences this risk<br />reduction was no longer statistically significant. 8.2% (178 of 2160) of the patients in the<br />olmesartan group and 9.8% (210 of 2139) in the placebo group developed microalbuminuria.<br />For the secondary endpoints, cardiovascular events occurred in 96 patients (4.3%) with olmesartan<br />and in 94 patients (4.2%) with placebo. The incidence of cardiovascular mortality was higher with<br />olmesartan compared to placebo treatment (15 patients (0.7%) vs. 3 patients (0.1%)), despite<br />similar rates for non-fatal stroke (14 patients (0.6%) vs. 8 patients (0.4%)), non-fatal myocardial<br />infarction (17 patients (0.8%) vs. 26 patients (1.2%)) and non-cardiovascular mortality (11 patients<br />(0.5%) vs. 12 patients (0.5%)). Overall mortality with olmesartan was numerically increased (26<br />patients (1.2%) vs. 15 patients (0.7%)), which was mainly driven by a higher number of fatal<br />cardiovascular events.<br />The Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic Nephropathy Trial<br />(ORIENT) investigated the effects of olmesartan on renal and cardiovascular outcomes in 577<br />randomized Japanese and Chinese type 2 diabetic patients with overt nephropathy. During a<br />median follow-up of 3.1 years, patients received either olmesartan or placebo in addition to other<br />antihypertensive agents including ACE inhibitors.</p><p>The primary composite endpoint (time to first event of the doubling of serum creatinine, end-stage<br />renal disease, all-cause death) occurred in 116 patients in the olmesartan group (41.1%) and 129<br />patients in the placebo group (45.4%) (HR 0.97 (95% CI 0.75 to 1.24); p=0.791). The composite<br />secondary cardiovascular endpoint occurred in 40 olmesartan-treated patients (14.2%) and 53<br />placebo-treated patients (18.7%). This composite cardiovascular endpoint included cardiovascular<br />death in 10 (3.5%) patients receiving olmesartan versus 3 (1.1%) receiving placebo, overall<br />mortality 19 (6.7%) versus 20 (7.0%), non-fatal stroke 8 (2.8%) versus 11 (3.9%) and non-fatal<br />myocardial infarction 3 (1.1%) versus 7 (2.5%), respectively.<br />Amlodipine (active ingredient of Olneda)<br />The amlodipine component of Olneda is a calcium channel blocker that inhibits the transmembrane<br />influx of calcium ions through the potential-dependent L-type channels into the heart and smooth<br />muscle. Experimental data indicate that amlodipine binds to both dihydropyridine and nondihydropyridine<br />binding sites. Amlodipine is relatively vessel-selective, with a greater effect on<br />vascular smooth muscle cells than on cardiac muscle cells. The antihypertensive effect of<br />amlodipine derives from a direct relaxant effect on arterial smooth muscle, which leads to a<br />lowering of peripheral resistance and hence of blood pressure.<br />In hypertensive patients, amlodipine causes a dose-dependent, long-lasting reduction in arterial<br />blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during<br />long-term treatment, or of rebound hypertension after abrupt cessation of therapy.<br />Following administration of therapeutic doses to patients with hypertension, amlodipine produces<br />an effective reduction in blood pressure in the supine, sitting and standing positions. Chronic use<br />of amlodipine is not associated with significant changes in heart rate or plasma catecholamine<br />levels. In hypertensive patients with normal renal function, therapeutic doses of amlodipine reduce<br />renal vascular resistance and increase glomerular filtration rate and effective renal plasma flow,<br />without changing filtration fraction or proteinuria.<br />In haemodynamic studies in patients with heart failure and in clinical studies based on exercise<br />tests in patients with NYHA class II-IV heart failure, amlodipine was found not to cause any</p><p>clinical deterioration, as measured by exercise tolerance, left ventricular ejection fraction and<br />clinical signs and symptoms.<br />A placebo-controlled study (PRAISE) designed to evaluate patients with NYHA class III-IV heart<br />failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to<br />an increase in risk of mortality or combined mortality and morbidity in patients with heart failure.<br />In a follow-up, long-term, placebo controlled study (PRAISE-2) of amlodipine in patients with<br />NYHA III and IV heart failure without clinical symptoms or objective findings suggestive of<br />underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics,<br />amlodipine had no effect on total or cardiovascular mortality. In this same population amlodipine<br />was associated with increased reports of pulmonary oedema despite no significant difference in<br />the incidence of worsening heart failure as compared to placebo.<br />Treatment to prevent heart attack trial (ALLHAT)<br />A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-<br />Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer<br />drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACEinhibitor)<br />as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild<br />to moderate hypertension.&rdquo;<br />A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean<br />of 4.9 years. The patients had at least one additional CHD risk factor, including: previous<br />myocardial infarction or stroke (&gt; 6 months prior to enrolment) or documentation of other<br />atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left<br />ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current<br />cigarette smoking (21.9%).<br />The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was<br />no significant difference in the primary endpoint between amlodipine-based therapy and<br />chlorthalidone-based therapy: RR 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints,&nbsp;the incidence of heart failure (component of a composite combined cardiovascular endpoint) was<br />significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs.<br />7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in allcause<br />mortality between amlodipine-based therapy and chlorthalidone-based therapy (RR 0.96<br />95% CI [0.89-1.02] p=0.20).<br />Other information:<br />Two large randomised, controlled trials (ONTARGET (Ongoing Telmisartan Alone and in<br />combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs<br />Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an<br />angiotensin II receptor blocker.<br />ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular<br />disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA<br />NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes<br />and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension<br />as compared to monotherapy was observed. Given their similar pharmacodynamic properties,<br />these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.<br />ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly<br />in patients with diabetic nephropathy.<br />ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease<br />Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an<br />ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and<br />chronic kidney disease, cardiovascular disease, or both. The study was terminated early because<br />of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically<br />more frequent in the aliskiren group than in the placebo group and adverse events and serious&nbsp;adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more<br />frequently reported in the aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following oral intake of Olneda, peak plasma concentrations of olmesartan and amlodipine are<br />reached at 1.5 &ndash; 2 h and 6 &ndash; 8 hours, respectively. The rate and extent of absorption of the two<br />active substances from Olneda are equivalent to the rate and extent of absorption following intake<br />of the two components as separate tablets. Food does not affect the bioavailability of olmesartan<br />and amlodipine from Olneda.<br />Olmesartan medoxomil (active ingredient of Olneda)<br />Absorption and distribution:<br />Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active<br />metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from<br />the gastrointestinal tract. No intact olmesartan medoxomil or intact side chain medoxomil moiety<br />have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a<br />tablet formulation was 25.6%.<br />The mean peak plasma concentration (Cmax) of olmesartan is reached within about 2 hours after<br />oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase<br />approximately linearly with increasing single oral doses up to about 80 mg.<br />Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil<br />may be administered with or without food.<br />No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have been<br />observed.<br />Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant<br />protein binding displacement interactions between olmesartan and other highly bound<br />coadministered active substances is low (as confirmed by the lack of a clinically significant&nbsp;interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells<br />is negligible. The mean volume of distribution after intravenous dosing is low (16 &ndash; 29 L).<br />Biotransformation and elimination:<br />Total plasma clearance of olmesartan was typically 1.3 L/h (CV, 19%) and was relatively slow<br />compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of 14C-labelled<br />olmesartan medoxomil, 10% &ndash; 16% of the administered radioactivity was excreted in the urine<br />(the vast majority within 24 hours of dose administration) and the remainder of the recovered<br />radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be<br />calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepato-biliary<br />excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other significant<br />metabolite was detected. Enterohepatic recycling of olmesartan is minimal. Since a large<br />proportion of olmesartan is excreted via the biliary route, use in patients with biliary obstruction<br />is contraindicated (see section 4.3).<br />The terminal elimination half life of olmesartan is between 10 and 15 hours after multiple oral<br />dosing. Steady state is reached after the first few doses and no further accumulation is evident after<br />14 days of repeated dosing. Renal clearance is approximately 0.5 &ndash; 0.7 L/h and is independent of<br />dose.<br />Drug interactions<br />Bile acid sequestering agent colesevelam:<br />Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam<br />hydrochloride in healthy subjects resulted in 28% reduction in Cmax and 39% reduction in AUC of<br />olmesartan. Lesser effects, 4% and 15% reduction in Cmax and AUC respectively, were observed<br />when olmesartan medoxomil was administered 4 hours prior to colesevelam hydrochloride.<br />Elimination half life of olmesartan was reduced by 50 &ndash; 52% irrespectively of whether<br />administered concomitantly or 4 hours prior to colesevelam hydrochloride (see section 4.5).</p><p>Amlodipine (active ingredient of Olneda)<br />Absorption and distribution:<br />After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels<br />between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and<br />80%. The volume of distribution is approximately 21 l/kg. In vitro studies have shown that<br />approximately 97.5% of circulating amlodipine is bound to plasma proteins.<br />The absorption of amlodipine is unaffected by the concomitant intake of food.<br />Biotransformation and elimination:<br />The terminal plasma elimination half life is about 35-50 hours and is consistent with once daily<br />dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of<br />the parent compound and 60% of metabolites excreted in the urine.<br />Olmesartan medoxomil and amlodipine (active ingredients of Olneda)<br />Special populations<br />Paediatric population (age below 18 years):<br />No pharmacokinetic data in paediatric patients are available.<br />Elderly (age 65 years or over):<br />In hypertensive patients, the olmesartan AUC at steady state is increased by ca 35% in elderly<br />people (65 &ndash; 75 years old) and by ca 44% in very elderly people (&ge; 75 years old) compared with<br />the younger age group (see section 4.2). This may be at least in part related to a mean decrease in<br />renal function in this group of patients. The recommended dosage regimen for elderly people is,<br />however, the same, although caution should be exercised when increasing the dosage.<br />The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger<br />subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and&nbsp;elimination half life in elderly people. Increases in AUC and elimination half life in patients with<br />congestive heart failure were as expected for the patient age group in this study (see section 4.4).<br />Renal impairment:<br />In renally impaired patients, the olmesartan AUC at steady state increased by 62%, 82% and 179%<br />in patients with mild, moderate and severe renal impairment, respectively, compared to healthy<br />controls (see sections 4.2, 4.4).<br />Amlodipine is extensively metabolised to inactive metabolites. Ten percent of the substance is<br />excreted unchanged in the urine. Changes in amlodipine plasma concentration are not correlated<br />with the degree of renal impairment. In these patients, amlodipine may be administered at the<br />normal dosage. Amlodipine is not dialysable.<br />Hepatic impairment:<br />After single oral administration, olmesartan AUC values are 6% and 65% higher in mildly and<br />moderately hepatically impaired patients, respectively, than in their corresponding matched<br />healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in<br />patients with mild hepatic impairment and in patients with moderate hepatic impairment is 0.26%,<br />0.34% and 0.41%, respectively. Following repeated dosing in patients with moderate hepatic<br />impairment, olmesartan mean AUC is again about 65% higher than in matched healthy controls.<br />Olmesartan mean Cmax values are similar in hepatically-impaired and healthy subjects.<br />Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment (see<br />sections 4.2, 4.4).<br />Very limited clinical data are available regarding amlodipine administration in patients with<br />hepatic impairment. The clearance of amlodipine is decreased and the half-life is prolonged in<br />patients with impaired hepatic function, resulting in an increase in AUC of about 40% &ndash; 60% (see<br />sections 4.2, 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on the non-clinical toxicity profile of each substance, no exacerbation of toxicities for the<br />combination is expected, because each substance has different targets, i.e. the kidneys for<br />olmesartan medoxomil and the heart for amlodipine.<br />In a 3-month, repeat-dose toxicity study of orally administered olmesartan medoxomil/amlodipine<br />in combination in rats the following alterations were observed: decreases in red blood cell countrelated<br />parameters and kidney changes both of which might be induced by the olmesartan<br />medoxomil component; alterations in the intestines (luminal dilatation and diffuse mucosal<br />thickening of the ileum and colon), the adrenals (hypertrophy of the glomerular cortical cells and<br />vacuolation of the fascicular cortical cells), and hypertrophy of the ducts in the mammary glands<br />which might be induced by the amlodipine component. These alterations neither augmented any<br />of the previously reported and existing toxicity of the individual agents nor induced any new<br />toxicity, and no toxicologically synergistic effects were observed.<br />Olmesartan medoxomil (active ingredient of Olneda)<br />In chronic toxicity studies in rats and dogs, olmesartan medoxomil showed similar effects to other<br />AT1 receptor antagonists and ACE inhibitors: raised blood urea (BUN) and creatinine; reduction<br />in heart weight; reduction of red cell parameters (erythrocytes, haemoglobin, haematocrit);<br />histological indications of renal damage (regenerative lesions of the renal epithelium, thickening<br />of the basal membrane, dilatation of the tubules). These adverse effects caused by the<br />pharmacological action of olmesartan medoxomil have also occurred in preclinical trials on other<br />AT1 receptor antagonists and ACE inhibitors and can be reduced by simultaneous oral<br />administration of sodium chloride. In both species, increased plasma renin activity and<br />hypertrophy/hyperplasia of the juxtaglomerular cells of the kidney were observed. These changes,<br />which are a typical effect of the class of ACE inhibitors and other AT1 receptor antagonists, would<br />appear to have no clinical relevance.</p><p>Like other AT1 receptor antagonists olmesartan medoxomil was found to increase the incidence<br />of chromosome breaks in cell cultures in vitro. No relevant effects were observed in several in<br />vivo studies using olmesartan medoxomil at very high oral doses of up to 2000 mg/kg. The overall<br />data of a comprehensive genotoxicity testing program suggest that olmesartan is very unlikely to<br />exert genotoxic effects under conditions of clinical use.<br />Olmesartan medoxomil was not carcinogenic, in a 2-year study in rats nor in two 6-month<br />carcinogenicity studies in transgenic mice.<br />In reproductive studies in rats, olmesartan medoxomil did not affect fertility and there was no<br />evidence of a teratogenic effect. In common with other angiotensin II antagonists, survival of<br />offspring was reduced following exposure to olmesartan medoxomil and pelvic dilatation of the<br />kidney was seen after exposure of the dams in late pregnancy and lactation. In common with other<br />antihypertensive agents, olmesartan medoxomil was shown to be more toxic to pregnant rabbits<br />than to pregnant rats, however, there was no indication of a fetotoxic effect.<br />Amlodipine (active ingredient of Olneda)<br />Reproductive toxicology<br />Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of<br />labour and decreased pup survival at dosages approximately 50 times greater than the maximum<br />recommended dosage for humans based on mg/kg.<br />Impairment of fertility<br />There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females<br />14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human<br />dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with<br />amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg,<br />decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases<br />in sperm density and in the number of mature spermatids and Sertoli cells.</p><p>Carcinogenesis, mutagenesis<br />Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to<br />provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity.<br />The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical<br />dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for<br />rats.<br />Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.<br />*Based on patient weight of 50 kg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline Cellulose PH113<br />Croscarmellose Sodium<br />Microcrystalline cellulose(Avicel PH 112)<br />Lactose Anhydrous DC Gr.<br />Colloidal Silicon Dioxide-Aerosil 200<br />Magnesium Stearate<br />Opadry II 85F18422 White (Used in 20 mg/5 mg)<br />Opadry II 85F565034 Brown (used in 20 mg/10 mg and 40 mg/10 mg strength)<br />Opadry II 85F32004Yellow (used in 40 mg/5 mg strength)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.<br />Keep out of reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediate Container: 3X10&rsquo;s tablets packed in Alu &ndash; Alu blister<br />Secondary Container: Cartoon with PIL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O. Box 6267
Jeddah 21442
Tel: +966-12-6081111
Fax: +966-12-6081222.
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oct-2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>